SCHEMBL3479519

SCHEMBL3479519

Cc1ccccc1-c1cccc(CN2CCC3(CC2)C(=O)NC(=O)N3c2cccc(F)c2)c1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 6/20 0.73
MCHR1 Q99705 4/20 0.50
BACE2 Q9Y5Z0 1/20 0.46
HSD11B1 P28845 1/20 0.41
OPRM1 P35372 2/20 0.40
OPRD1 P41143 2/20 0.40
OPRK1 P41145 2/20 0.40
OPRL1 P41146 2/20 0.40
DRD2 P14416 2/20 0.40
DRD3 P35462 2/20 0.40
DOCK5 Q9H7D0 1/20 0.40
CACNA1F O60840 1/20 0.40
CHRM2 P08172 1/20 0.40
ADRB1 P08588 1/20 0.40
SLC6A2 P23975 1/20 0.40
ADRA1D P25100 1/20 0.40
ADRA1A P35348 1/20 0.40
HRH1 P35367 1/20 0.40
ADRA1B P35368 1/20 0.40
CACNA1D Q01668 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3479520 1.00 BACE1 (0.73) BACE1MCHR1BACE2HSD11B1OPRM1
Trifluoroacetic Acid SCHEMBL3479467 0.93 BACE1 (0.66) BACE1MCHR1BACE2HSD11B1OPRM1
SCHEMBL4253306 0.86 BACE1 (0.61) BACE1HSD11B1
SCHEMBL3479622 0.86 BACE1 (0.61) BACE1HSD11B1
SCHEMBL8209542 0.85 BACE1 (0.67) BACE1MCHR1BACE2OPRM1OPRD1
SCHEMBL3479574 0.84 BACE1 (0.63) BACE1BACE2HSD11B1DRD2DRD3
SCHEMBL593631 0.83 BACE1 (0.61) BACE1BACE2HSD11B1DRD2DRD3
SCHEMBL25916122 0.81 BACE1 (0.64) BACE1BACE2HSD11B1DRD2DRD3
SCHEMBL8197624 0.79 BACE1 (0.51) BACE1MCHR1BACE2OPRM1OPRD1
SCHEMBL593730 0.78 BACE1 (0.66) BACE1BACE2HSD11B1DOCK5SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100298342-A1 Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's Disease MERCK & CO., INC. (US) 2010-11-25 US claimed
US-20100298342-A1 Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's Disease MERCK & CO., INC. (US) 2010-11-25 US disclosed
US-20100298342-A1 Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's Disease MERCK & CO., INC. (US) 2010-11-25 US disclosed
EP-2063889-A2 SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE Merck & Co., Inc. (US) 2009-06-03 EP disclosed
WO-2008030412-A2 SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE MERCK & CO., INC. (US) 2008-03-13 WO disclosed
WO-2008030412-A2 SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE MERCK & CO., INC. (US) 2008-03-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298342-A1 Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's Disease BACE1, APP, PSEN1 BACE1 1/4885MCHR1 4417/4885BACE2 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.